Anti-angiogenic properties of calcium trifluoroacetate

被引:2
|
作者
Bussolati, Benedetta [2 ]
Ribatti, Domenico [3 ]
Munaron, Luca [4 ]
Bartorelli, Alberto [5 ]
Bussolati, Gianni [1 ]
机构
[1] Univ Turin, Dept Biomed Sci & Human Oncol, I-10126 Turin, Italy
[2] Univ Turin, Ctr Mol Biotechnol, Dept Internal Med, I-10126 Turin, Italy
[3] Univ Bari, Dept Human Anat & Histol, I-70121 Bari, Italy
[4] Univ Turin, Ctr Complex Syst Mol Biol & Med SyBioM, Nanostruct Interfaces & Surfaces Ctr Excellence N, Dept Anim & Human Biol, I-10126 Turin, Italy
[5] Univ Milan, I-20122 Milan, Italy
关键词
Angiogenesis; Calcium; Trifluoroacetate; NITRIC-OXIDE PRODUCTION; CHORIOALLANTOIC MEMBRANE; INTRACELLULAR CALCIUM; MECHANISMS; VEGF; PROLIFERATION;
D O I
10.1016/j.mvr.2009.07.001
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Endothelial cell proliferation and the formation of new vessels are strictly regulated by angiogenic factors (e.g., VEGF) that induce the activation of signal transduction pathways controlled by calcium dynamics. Using in vitro and in vivo experiments, we investigated the effect of calcium trifluoroacetate (CaTFAc), a complex, poorly dissociated salt that is characterized by its low toxicity, on angiogenesis. In vitro, CaTFAc inhibited VEGF-induced effects on endothelial cell proliferation. In two in vivo models of angiogenesis, a Matrigel plug in mice and a chick embryo chorioallantoic membrane, CaTFAc inhibited the VEGF-induced formation of new vessels. The exact mechanism of action is still under investigation, but in vitro experiments demonstrate that CaTFAc induced a reversible increase in the levels of intracellular calcium under basal conditions and prevented calcium signaling induced by VEGF. These results are the first to suggest that CaTFAc may be useful for the treatment of diseases caused by enhanced angiogenesis. (C) 2009 Elsevier Inc. All rights reserved.
引用
收藏
页码:272 / 277
页数:6
相关论文
共 50 条
  • [21] Anti-angiogenic Properties of Chemopreventive Drugs: Fenretinide as a Prototype
    Sogna, Ilaria
    Vene, Roberta
    Sapienza, Cristina
    Ferrari, Nicoletta
    Tosetti, Francesca
    Albini, Adriana
    CANCER PREVENTION II, 2009, 181 : 71 - 76
  • [22] Comparison of anti-angiogenic properties of pristine carbon nanoparticles
    Mateusz Wierzbicki
    Ewa Sawosz
    Marta Grodzik
    Marta Prasek
    Slawomir Jaworski
    André Chwalibog
    Nanoscale Research Letters, 8
  • [23] Resveratrol and related stilbenes: Their anti-aging and anti-angiogenic properties
    Kasiotis, Konstantinos M.
    Pratsinis, Harris
    Kletsas, Dimitris
    Haroutounian, Serkos A.
    FOOD AND CHEMICAL TOXICOLOGY, 2013, 61 : 112 - 120
  • [24] Anti-Angiogenic and Anti-Inflammatory Properties of Kahweol, a Coffee Diterpene
    Cardenas, Casimiro
    Quesada, Ana R.
    Medina, Miguel A.
    PLOS ONE, 2011, 6 (08):
  • [25] Combination of anti-angiogenic therapy and virotherapy: Arming oncolytic viruses with anti-angiogenic genes
    Tysome, James R.
    Lemoine, Nick R.
    Wang, Yaohe
    CURRENT OPINION IN MOLECULAR THERAPEUTICS, 2009, 11 (06) : 664 - 669
  • [26] Dieckol as a novel anti-proliferative and anti-angiogenic agent and computational anti-angiogenic activity evaluation
    Li, Yong-Xin
    Li, Yong
    Je, Jae-Young
    Kim, Se-Kwon
    ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY, 2015, 39 (01) : 259 - 270
  • [27] Anti-angiogenic activity of tocotrienol
    Inokuchi, H
    Hirokane, H
    Tsuzuki, T
    Nakagawa, K
    Igarashi, M
    Miyazawa, T
    BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY, 2003, 67 (07) : 1623 - 1627
  • [28] Anti-angiogenic strategies in glioblastoma
    Guillamo, J. -S.
    REVUE NEUROLOGIQUE, 2011, 167 (10) : 662 - 667
  • [29] Anti-angiogenic therapy for osteosarcoma
    Quan, Gerald M. Y.
    Choong, Peter F. M.
    CANCER AND METASTASIS REVIEWS, 2006, 25 (04) : 707 - 713
  • [30] Cancer anti-angiogenic therapy
    Shimizu, K
    Oku, N
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2004, 27 (05) : 599 - 605